Cargando...
Toxicity management for patients receiving novel T-cell engaging therapies
PURPOSE OF REVIEW: Recent clinical trials using T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cells, as well as engineered T cells that express targeting and activation molecules known as chimeric antigen receptors, have demonstrated powerful proof of c...
Gardado en:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4198063/ https://ncbi.nlm.nih.gov/pubmed/24362408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOP.0000000000000043 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|